Searched for
ASTRAZENECA DRUG DEVELOPMENT
Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancerAstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its impo...
- Novartis experimental actinium-based drug shows promise in prostate cancer treatment: StudyNovartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, e...
- What to know about the Bundibugyo virus, a species of Ebola causing an outbreak in CongoA rare Bundibugyo virus outbreak in Congo, with over 200 deaths, lacks specific treatments or vaccines, complicating response efforts. Whil...
- From diapers to drugs: How India's global corporate hubs are putting AI to workHeads of several Global Capability Centres (GCCs) told Reuters they are deploying AI across a host of functions - from marketing and conten...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- AstraZeneca sets up clinical data insights division in IndiaThe Bengaluru-based clinical data and insights (CDI) division is a critical advancement to support a growing global portfolio and build on ...
- AstraZeneca hits snag in Covid drug developmentThe drug, made from a combination of two antibodies, failed its main goal to treat Covid-19 symptoms in exposed patients, AstraZeneca said ...
- AstraZeneca sells cholesterol drug rights to Grünenthal for $320 millionAstraZeneca, which is among the front-runners in the race to develop a vaccine for the novel coronavirus, has been trying to focus on its c...
- India trials of COVID-19 vaccine is going on: Serum InstituteLast month, the Drug Controller General of India had granted permission to the Pune-based SII to conduct Phase-II and -III human clinical t...
- Dr Reddy's trades steady, shrugs off legal challengeDRL’s generic version was to be marketed as Ticaflo, according to those in the know.
- AstraZeneca sues DRL on patentCopies of the drug can be manufactured only after all the patents covering it expire, AstraZeneca’s counsel argued in court on Tuesday.
- High Court rejects AstraZeneca’s diabetes drug pleaThe Delhi High Court has dismissed AstraZeneca’s plea to block Hyderabadbased Lee Pharma from making copies of its anti-diabetes drug Ongly...
- AstraZeneca inaugurates global technology centre in ChennaiThe company is also looking to develop additional technology centres with a second GTC planned for San Francisco in 2015.
- Good cancer drug data helps AstraZeneca in Pfizer fightBritain's second-biggest drugmaker has rejected a $106 billion approach from its US rival Pfizer, arguing that it has a bright future.
- Cognizant inks multi-year agreement with AstraZenecaCognizant has inked a deal with AstraZeneca to deliver comprehensive biostatistics and medical reporting services for generating clinical s...
- Jubilant Biosys receives milestone payment from AstraZenecaEarlier this week Jubilant Biosys along with US-based Endo Pharmaceuticals received an undisclosed milestone payment for their joint progra...
- Ranbaxy strikes deal on Nexium with AstraZenecaRanbaxy has entered into a series of out-of-court settlements with AstraZeneca with estimates of a revenue upside of $1.25-1.5 billion. Go ...
- AstraZeneca to get drugs made in IndiaAstraZeneca, Britain’s second largest pharmaceutical company, is planning to outsource all its drug manufacturing activities to India and o...
Load More
